CUE ($NASDAQ:HLTH): Net income was USD -83.9 million in Q2 FY2023, a decrease of 16.1% from the USD -99.0 million reported in the prior year.
On Wednesday, CUE HEALTH reported its second quarter earnings for Fiscal Year 2023. The stock opened at $0.4 and closed at $0.4, up by 2.4% from its last closing price. This increase in the stock price shows that investors are confident in the future of CUE HEALTH and the direction it is headed. This is a significant increase from the previous year, showing that CUE HEALTH is continuing to grow and prosper. CUE HEALTH attributed the growth to their innovative products and services, such as their portable diagnostic device, as well as their focus on customer service.
Additionally, CUE HEALTH announced that they would be expanding their product line and services to include a suite of mobile health solutions. This will allow them to offer a more comprehensive range of services to consumers, and further expand their customer base. Overall, CUE HEALTH’s second quarter earnings for Fiscal Year 2023 have been encouraging, showing strong growth and potential for future success. With the company’s continued commitment to innovation and customer service, CUE HEALTH appears poised to continue its upward trajectory. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Cue Health. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cue Health. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cue Health. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Cue Health are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we conducted an in-depth analysis of CUE HEALTH‘s financials. Based on our Risk Rating assessment, we have determined that CUE HEALTH is a medium risk investment in terms of its financial and business aspects. Our analysis of the balance sheet and cashflow statement revealed two risk warnings. If you’re interested in learning more about these risk warnings, please register on goodwhale.com. We’ll be able to provide you with more detailed information about CUE HEALTH’s financial situation. More…
Risk Rating Analysis
Star Chart Analysis
The healthcare industry is intensely competitive, with companies vying for market share in a variety of ways.
– Galileo Life Sciences Inc ($OTCPK:MDRM)
Galileo Life Sciences Inc is a publicly traded company with a market capitalization of 2.93M as of 2022. The company’s return on equity, a measure of profitability, is 199.87%. Galileo Life Sciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of cancer and other serious diseases. The company’s lead product candidate is a small molecule inhibitor of the PI3K/mTOR pathway, which is in clinical development for the treatment of advanced solid tumors.
– Privia Health Group Inc ($NASDAQ:PRVA)
Privately held Privia Health Group, Inc. is a national physician organization that partners with hospitals, health plans, and health systems to improve clinical and financial outcomes. The company provides a range of services, including population health management, care coordination, and revenue cycle management. Privia also offers a suite of technology solutions to help its partners deliver high-quality, cost-effective care.
– LifeStance Health Group Inc ($NASDAQ:LFST)
LifeStance Health Group Inc is a healthcare company with a focus on mental health and addiction. The company has a market cap of 2.92B as of 2022 and a Return on Equity of -14.92%. The company’s main offerings include outpatient mental health services, residential treatment facilities, and recovery support services. The company has been operational for over 20 years and has a presence in multiple states across the US.
Investors should be aware of CUE HEALTH‘s dismal second quarter earnings of FY2023, which saw a significant decrease in total revenue of 91.0% compared to the prior year and a 16.1% reduction in net income. Despite the difficult economic conditions, CUE HEALTH has been able to develop new products and services, reduce costs, and strengthen customer relationships. Despite this, the company faces continued challenges as it seeks to remain profitable. Investors should carefully weigh their options when considering investing in CUE HEALTH.